Sertindole: efficacy and safety in schizophrenia.
Sertindole is an antipsychotic drug with affinity for dopamine D2, serotonin 5-HT2A and 5-HT2C, and alpha1-adrenoreceptors. Preclinical studies suggest that sertindole acts preferentially on limbic and cortical dopaminergic neurons and clinical trials have confirmed that sertindole is effective at a low dopamine D2 occupancy level. The active substance has a long half-life. Oral administration once daily yields highly stable plasma levels. These features may explain the clinically observed low frequency of extrapyramidal side effects, including tardive dyskinesia. In contrast to most antipsychotics, sertindole seems to be void of sedative effects. However, although not strictly proven by objective neuropsychological tests, this asset of sertindole does not add to the cognitive problems inherent in schizophrenia. Administration of sertindole is more often associated with prolongation of QTc compared with most other currently used antipsychotics. However, large cohort analyses do not suggest that all-cause mortality is higher with sertindole than with, for example, risperidone or olanzapine. The effective antipsychotic dose range of sertindole is 12-20 mg/day, with small variations among patients. The frequency of most adverse events, for example extrapyramidal symptoms and somnolence, with such a dose does not differ from placebo. Three side effects have been more common than with placebo/haloperidol in short-term studies: weight gain, rhinitis and a decreased ejaculation volume. Two head-to-head comparisons (one in treatment-resistant patients) of sertindole and risperidone showed equivalent effects on positive symptoms. For negative symptoms, one study obtained equivalent effects and one a superior effect of sertindole. Sertindole should not be used as first-line treatment for first-episode patients with schizophrenia because of the QTc prolongation. It has a side-effect profile that makes it an interesting alternative for many patients who do not respond well to the initial choice of antipsychotic drug.
Lindström
Eva
E
Department of Neurosience, Psychiatry, Uppsala University Hospital, SS-750 17 Uppsala, Sweden. eva.lindstrom@akademiska.se
Levander
Sten
S
D000818:Animals; D064420:Drug-Related Side Effects and Adverse Reactions; D006262:Health; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects* / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D007211:Indoles / Q000009:adverse effects* / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D012559:Schizophrenia / Q000145:classification / Q000188:drug therapy* / Q000473:pathology
D007093:Imidazoles; D007211:Indoles; C066304:sertindole